For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

I.V. AUGMENTIN 300 mg / 600 mg / 1.2 g

Amoxycillin and Potassium Clavulanate Injection IP 300 mg / 600 mg / 1.2 g

QUALITATIVE AND QUANTITATIVE COMPOSITION

I.V. AUGMENTIN 300 mg:

Each vial contains:
Amoxycillin Sodium IP (Sterile) 265 mg equivalent to Amoxycillin 250 mg
Potassium Clavulanate IP (Sterile) 60 mg equivalent to Clavulanic Acid 50 mg

I.V. AUGMENTIN 600 mg:

Each vial contains:
Amoxycillin Sodium IP (Sterile) 530 mg equivalent to Amoxycillin 500 mg
Potassium Clavulanate IP (Sterile) 119 mg equivalent to Clavulanic Acid 100 mg

I.V. AUGMENTIN 1.2 g:

Each vial contains:
Amoxycillin Sodium IP (Sterile) 1060 mg equivalent to Amoxycillin 1000 mg
Potassium Clavulanate IP (Sterile) 238 mg equivalent to Clavulanic Acid 200 mg

PHARMACEUTICAL FORM

Sterile powder for injection.

CLINICAL PARTICULARS

Therapeutic Indications

AUGMENTIN should be used in accordance with local official antibiotic-prescribing

guidelines and local susceptibility data.

I.V. AUGMENTIN is indicated for short-term treatment of bacterial infections at the

following sites:

Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis,
otitis media.

Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar and
bronchopneumonia.

Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.

1
Skin and soft tissue infections, e.g. boils, abscesses, cellulitis, wound infections.

Bone and joint infections e.g. osteomyelitis.

Other infections e.g. intra-abdominal sepsis.

I.V. AUGMENTIN is also indicated for prophylaxis against infection which may be
associated with major surgical procedures such as gastrointestinal, pelvic, head and neck,
cardiac, renal, joint replacement and biliary tract.

Susceptibility to AUGMENTIN will vary with geography and time (see Pharmacological
Properties, Pharmacodynamic Properties for further information). Local susceptibility
data should be consulted where available, and microbiological sampling and susceptibility
testing performed where necessary.

Infections caused by amoxycillin-susceptible organisms are amenable to AUGMENTIN

treatment due to its amoxycillin content. Mixed infections caused by amoxycillin -
susceptible organisms in conjunction with AUGMENTIN-susceptible β-lactamase
producing organisms may therefore be treated with AUGMENTIN.

Posology and Method of Administration

• Dosage for the treatment of infections

Adults and children over 12 years:Usually 1.2 g eight hourly. In more

serious infections, increase frequency
to six-hourly intervals.
Children 3 months-12 years: Usually 30 mg/kg* AUGMENTIN eight
hourly. In more serious infections,
increase frequency to six-hourly
intervals.
Children 0-3 months: 30 mg/kg* AUGMENTIN every 12
hours in premature infants and in full
term infants during the perinatal period,
increasing to eight hours thereafter.
* Each 30 mg AUGMENTIN contains 25 mg amoxycillin and 5 mg clavulanate.

• Adult dosage for surgical prophylaxis

The usual dose is 1.2 g I.V. AUGMENTIN given at the induction of anaesthesia. Operations
where there is a high risk of infection, e.g. colorectal surgery, may require three, and up to
four, doses of 1.2 g I.V. AUGMENTIN in a 24-hour period. These doses are usually given
at 0, 8, 16 (and 24) hours. This regimen can be continued for several days if the procedure
has a significantly increased risk of infection.

2
Clear clinical signs of infection at operation will require a normal course of intravenous or
oral AUGMENTIN therapy post-operatively.

• Dosage in renal impairment

Adults

Mild impairment Moderate impairment Severe impairment

(creatinine clearance (creatinine clearance (creatinine clearance
>30 ml/min) 10-30 ml/min) <10 ml/min)
No change in dosage 1.2 g IV stat., 1.2 g IV stat., followed by 600
followed by 600 mg mg IV 24 hourly. Dialysis
IV 12 hourly decreases serum
concentrations of
AUGMENTIN and an
additional 600 mg IV dose
may need to be given during
dialysis and at the end of
dialysis

Children

Similar reductions in dosage should be made for children.

• Dosage in hepatic impairment

Dose with caution; monitor hepatic function at regular intervals.

Each 1.2 g vial of AUGMENTIN contains 1.0 mmol of potassium and 3.1 mmol of sodium
(approx.).

Method of Administration

I.V. AUGMENTIN may be administered either by intravenous injection or by intermittent

infusion. It is not suitable for intramuscular administration.

Contraindications

AUGMENTIN is contraindicated in patients with a history of hypersensitivity to beta-

lactams, e.g. penicillins and cephalosporins

AUGMENTIN is contraindicated in patients with a previous history of AUGMENTIN-

associated jaundice/hepatic dysfunction.

3
Special Warnings and Special Precautions for Use

Before initiating therapy with AUGMENTIN, careful enquiry should be made concerning
previous hypersensitivity reactions, cephalosporins, or other allergens.

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and

severe cutaneous adverse reactions) have been reported in patients on penicillin therapy.
These reactions are more likely to occur in individuals with a history of penicillin
hypersensitivity (see Contraindications). If an allergic reaction occurs, AUGMENTIN
therapy must be discontinued and appropriate alternative therapy instituted. Serious
anaphylactic reactions require immediate emergency treatment with adrenaline. Oxygen,
intravenous (i.v.) steroids and airway management (including intubation) may also be
required.

Changes in liver function tests have been observed in some patients receiving
AUGMENTIN. The clinical significance of these changes is uncertain but AUGMENTIN
should be used with caution in patients with evidence of hepatic dysfunction.

Cholestatic jaundice, which may be severe, but is usually reversible, has been reported
rarely. Signs and symptoms may not become apparent for up to six weeks after treatment
has ceased.

In patients with renal impairment AUGMENTIN dosage should be adjusted as

recommended in the Posology and Method of Administration section.

AUGMENTIN should be avoided if infectious mononucleosis is suspected since the

occurrence of a morbilliform rash has been associated with this condition following the use
of amoxycillin.

Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.

Pseudomembranous colitis has been reported with the use of antibiotics and may range in
severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in
patients who develop diarrhoea during or after antibiotic use. If prolonged or significant
diarrhoea occurs or the patient experiences abdominal cramps, treatment should be
discontinued immediately and the patient investigated further.

Abnormal prolongation of prothrombin time [increased International Normalized Ratio

(INR)] has been reported rarely in patients receiving AUGMENTIN and oral
anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are
prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary
to maintain the desired level of anticoagulation.

If the parenteral administration of high doses is necessary, the sodium content must be
taken into account in patients on a sodium restricted diet.

4
In patients with reduced urine output crystalluria has been observed very rarely,
predominantly with parenteral therapy. During administration of high doses of amoxycillin
it is advisable to maintain adequate fluid intake and urinary output in order to reduce the
possibility of amoxycillin crystalluria (see Overdose).

The presence of clavulanic acid in AUGMENTIN may cause a non-specific binding of IgG
and albumin by red cell membranes leading to a false positive Coombs test.

Interaction with Other Medicaments and Other Forms of Interaction

Concomitant use of probenecid is not recommended. Probenecid decreases the renal

tubular secretion of amoxycillin. Concomitant use with AUGMENTIN may result in
increased and prolonged blood levels of amoxycillin but not of clavulanate.

Concomitant use of allopurinol during treatment with amoxycillin can increase the
likelihood of allergic skin reactions. There are no data on the concomitant use of
AUGMENTIN and allopurinol.

In common with other antibiotics, AUGMENTIN may affect the gut flora, leading to lower
oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

The presence of clavulanic acid in AUGMENTIN may cause a non-specific binding of IgG
and albumin by red cell membranes leading to a false positive Coombs test.

In the literature there are rare cases of increased international normalised ratio in patients
maintained on acenocoumarol or warfarin and prescribed a course of amoxycillin. If co-
administration is necessary, the prothrombin time or international normalised ratio should
be carefully monitored with the addition or withdrawal of AUGMENTIN.

In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the

active metabolite mycophenolic acid of approximately 50% has been reported following
commencement of oral amoxycillin plus clavulanic acid. The change in pre-dose level may
not accurately represent changes in overall MPA exposure.

Pregnancy and Lactation

Use in Pregnancy

Reproduction studies in animals (mice and rats) with orally and parenterally administered
AUGMENTIN have shown no teratogenic effects. In a single study in women with preterm,
premature rupture of the foetal membrane (pPROM), it was reported that prophylactic
treatment with AUGMENTIN may be associated with an increased risk of necrotising
enterocolitis in neonates. As with all medicines, use should be avoided in pregnancy,
especially during the first trimester, unless considered essential by the physician.

5
Use in Lactation

AUGMENTIN may be administered during the period of lactation. With the exception of
the risk of sensitisation, associated with the excretion of trace quantities in breast milk,
there are no detrimental effects for the infant.

Effects on Ability to Drive and Use Machines

Adverse effects on the ability to drive or operate machinery have not been observed.

Undesirable Effects

Data from large clinical trials were used to determine the frequency of very common to
rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e., those
occurring at <1/10,000) were mainly determined using post-marketing data and refer to a
reporting rate rather than a true frequency.

The following convention has been used for the classification of frequency:

Very common ≥ 1/10

Common ≥ 1/100 and < 1/10
Uncommon ≥ 1/1000 and < 1/100
Rare ≥ 1/10,000 and < 1/1000
Very rare < 1/10,000

Infections and infestations

Common Mucocutaneous candidiasis

Blood and lymphatic system disorders

Rare Reversible leucopenia (including neutropenia) and thrombocytopenia

Very rare Reversible agranulocytosis and haemolytic anaemia. Prolongation of

bleeding time and prothrombin time

Immune system disorders

Very rare Angioneurotic oedema, anaphylaxis, serum sickness-like syndrome,

hypersensitivity vasculitis

Nervous system disorders

Uncommon Dizziness, headache

6
Very rare Convulsions. Convulsions may occur in patients with impaired renal
function or in those receiving high doses.

Vascular disorders

Rare Thrombophlebitis at the site of injection

Gastrointestinal disorders

Common Diarrhoea

Uncommon Nausea, vomiting, indigestion

Very rare Antibiotic-associated colitis (including pseudomembranous colitis and

haemorrhagic colitis– see Special Warnings and Special Precautions for
use) are less likely to occur after parenteral administration.

Hepatobiliary disorders

Uncommon A moderate rise in AST and/or ALT has been noted in patients treated with
beta-lactam class antibiotics, but the significance of these findings is
unknown.

Very rare Hepatitis and cholestatic jaundice. These events have been noted with other
penicillins and cephalosporins.

Hepatic events have been reported predominantly in males and elderly patients and may be
associated with prolonged treatment.

Signs and symptoms usually occur during or shortly after treatment but in some cases may
not become apparent until several weeks after treatment has ceased. These are usually
reversible. Hepatic events may be severe and in extremely rare circumstances, deaths have
been reported. These have almost always occurred in patients with serious underlying
disease or taking concomitant medications known to have the potential for hepatic effects.

Skin and subcutaneous tissue disorders

Uncommon Skin rash, pruritus, urticaria

Rare Erythema multiforme

Very rare Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative-

dermatitis, acute generalised exanthemous pustulosis (AGEP), drug
reaction with eosinophilia and systemic symptoms (DRESS)

If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued.

7
Renal and urinary disorders

Very rare Interstitial nephritis, crystalluria (see Overdose)

Overdose

Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be
evident. Gastrointestinal symptoms may be treated symptomatically with attention to the
water electrolyte balance.

Amoxycillin crystalluria, in some cases leading to renal failure, has been observed (see
Special Warnings and Special Precautions for Use).

AUGMENTIN can be removed from the circulation by haemodialysis.

Amoxycillin has been reported to precipitate in bladder catheters after intravenous

administration of large doses. A regular check of patency should be maintained.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties

Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic
before it can act on the pathogen. The clavulanate in AUGMENTIN anticipates this defence
mechanism by blocking the ß-lactamase enzymes, thus rendering the organisms sensitive
to amoxycillin’s rapid bactericidal effect at concentrations readily attainable in the body.

Clavulanate by itself has little antibacterial activity; however, in association with

amoxycillin as AUGMENTIN, it produces an antibiotic agent of broad spectrum with wide
application in hospital and general practice.

In the list below, organisms are categorised according to their in vitro susceptibility to
AUGMENTIN.

In vitro susceptibility of micro-organisms to AUGMENTIN

Where clinical efficacy of AUGMENTIN has been demonstrated in clinical trials this is
indicated with an asterisk (*).

Organisms that do not produce beta-lactamase are identified (with †). If an isolate is
susceptible to amoxycillin, it can be considered susceptible to AUGMENTIN.

Commonly susceptible species

Gram-positive aerobes:
Bacillius anthracis
Enterococcus faecalis

8
Gardnerella vaginalis
Listeria monocytogenes
Nocardia asteroides
Streptococcus pneumoniae*†
Streptococcus pyogenes*†
Streptococcus agalactiae*†
Viridans group streptococcus†
Streptococcus spp. (other β-hemolytic)*†
Staphylococcus aureus (methicillin susceptible)*
Staphylococcus saprophyticus (methicillin susceptible)
Coagulase negative staphylococcus (methicillin susceptible)
Gram-negative aerobes:
Bordetella pertussis
Haemophilus influenzae*
Haemophilus parainfluenzae
Helicobacter pylori
Moraxella catarrhalis*
Neisseria gonorrhoeae
Pasteurella multocida
Vibrio cholerae
Other:
Borrelia burgdorferi
Leptospira ictterohaemorrhagiae
Treponema pallidum
Gram-positive anaerobes:
Clostridium spp.
Peptococcus niger
Peptostreptococcus magnus
Peptostreptococcus micros
Peptostreptococcus spp.
Gram-negative anaerobes:
Bacteroides fragilis
Bacteroides spp.
Capnocytophaga spp.
Eikenella corrodens
Fusobacterium nucleatum
Fusobacterium spp.
Porphyromonas spp.
Prevotella spp.
Species for which acquired resistance may be a problem

9
 Gram-negative aerobes:
Escherichia coli*
Klebsiella oxytoca
Klebsiella pneumoniae*
Klebsiella spp.
Proteus mirabilis
Proteus vulgaris
Proteus spp.
Salmonella spp.
Shigella spp
Gram-positive aerobes:
Corynebacterium spp.
Enterococcus faeciium
Inherently resistant organisms
Gram-negative aerobes:
Acinetobacter spp.
Citrobacter freundii
Enterobacter spp.
Hafnia alvei
Legionella pneumophila
Morganella morganii
Providencia spp.
Pseudomonas spp.
Serratia spp.
Stenotrophomas maltophilia
Yersinia enterolitica
Others:
Chlamydia pneumoniae
Chlamydia psittaci
Chlamydia spp.
Coxiella burnetti
Mycoplasma spp.

Pharmacokinetic Properties

The pharmacokinetics of the two components of AUGMENTIN are closely matched. Both
clavulanate and amoxycillin have low levels of serum binding; about 70% remains free in
the serum.

Doubling the dosage of AUGMENTIN approximately doubles the serum levels achieved.

Preclinical Safety Data

No further information of relevance.

10
PHARMACEUTICAL PARTICULARS

List of Excipients

None.

Incompatibilities

I.V. AUGMENTIN should not be mixed with blood products, other proteinaceous fluids
such as protein hydrolysates or with intravenous lipid emulsions.

If AUGMENTIN is prescribed concurrently with an aminoglycoside, the antibiotics should

not be mixed in the syringe, intravenous fluid container or giving set because loss of
activity of the aminoglycoside can occur under these conditions.

Shelf Life

The expiry date is indicated on the label and packaging.

Special Precautions for Storage

300 mg vial: Store at a temperature between 2°C to 8°C.

600 mg vial: Store at a temperature not exceeding 25°C.

1.2 g vial: Store at a temperature not exceeding 25°C.

Keep out of reach of children.

Nature and Specification of Container

Clear glass vial in a carton.

All presentations may not be marketed in the country.

Instructions for Use/Handling

SINGLE USE VIAL ONLY

300 mg vial: To reconstitute dissolve in 5 ml sterile Water for Injection IP (Final volume
5.25 ml)

600 mg vial: To reconstitute dissolve in 10 ml sterile Water for Injection IP (Final

volume 10.5 ml)

11
1.2 g vial: To reconstitute dissolve in 20 ml sterile Water for Injection IP (Final volume
20.9 ml)

A transient pink coloration may or may not appear during reconstitution. Reconstituted
solutions are normally colourless or a pale, straw colour.

Intravenous Injection:

The stability of I.V. AUGMENTIN solution is concentration dependent, thus I.V.

AUGMENTIN should be used immediately upon reconstitution and given by slow
intravenous injection over a period of 3-4 minutes. I.V. AUGMENTIN solutions should be
used within 20 minutes of reconstitution. AUGMENTIN may be injected directly into a
vein or via a drip tube.

Intravenous Infusion:

Alternatively, I.V. AUGMENTIN may be infused in Water for Injections IP or Sodium

Chloride Intravenous Injection IP (0.9% w/v). Add, without delay*, 600 mg reconstituted
solution to 50 ml infusion fluid or 1.2 g reconstituted solution to 100 ml infusion fluid (e.g.
using a minibag or in-line burette). Infuse over 30-40 minutes and complete within four
hours of reconstitution. For other appropriate infusion fluids, see Stability and
Compatibility section.

*Solutions should be made up to full infusion volume immediately after reconstitution.

Any residual antibiotic solutions should be discarded.

Therapy can be started parenterally and continued with an oral preparation. Treatment
should not be extended beyond 14 days without review.

Stability and Compatibility

Intravenous infusions of AUGMENTIN may be given in a range of different intravenous

fluids. Satisfactory antibiotic concentrations are retained at 5°C and at room temperature
(25°C) in the recommended volume of the following infusion fluids. If reconstituted and
maintained at room temperature, infusions should be completed within the times stated.

Intravenous infusion fluids Stability period at 25°C

Water for Injections IP 4 hours

Sodium Chloride Intravenous 4 hours

Infusion IP (0.9% w/v)
Sodium Lactate Intravenous Infusion 4 hours
IP (one-sixth molar)

12
 Compound Sodium Chloride 3 hours
Intravenous Infusion IP (Ringer's
Solution)
Compound Sodium Lactate 3 hours
Intravenous Infusion IP (Ringer-
Lactate Solution; Hartmann's
Solution)

Potassium Chloride and Sodium 3 hours

Chloride Intravenous Infusion IP

Reconstituted solutions should not be frozen.

AUGMENTIN is less stable in infusions containing glucose, dextran or bicarbonate.

Reconstituted solutions of AUGMENTIN should therefore not be added to such infusions
but may be injected into the drip tubing over a period of 3-4 minutes.

For storage at 5°C, the reconstituted solution should be added to pre-refrigerated infusion
bags which can be stored for up to 8 hours. Thereafter, the infusion should be administered
immediately after reaching room temperature.

Intravenous infusion fluids Stability period at 5°C

Water for Injections IP 8 hours
Sodium Chloride Intravenous 8 hours
Infusion IP (0.9% w/v)

For further information please contact:

GlaxoSmithKline Pharmaceuticals Limited.
Registered Office
Dr. Annie Besant Road, Worli
Mumbai 400 030. India.

Trade marks are owned by or licensed to the GSK group of companies.

Version: AUG-IV/PI/IN/2017/03 dated 12-Dec-2017.

Adapted from Augmentin IV GDS version 30 / IPI version 11 dated 15 August 2017.

13